XESX:LSE:LSE-Xtrackers Euro Stoxx 50 UCITS ETF 1D (GBX)

ETF | Others |

Last Closing

USD 4544.75

Change

+114.75 (+2.59)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

-2.95 (-1.70%)

USD 1,607.29B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.13 (+0.69%)

USD 640.06B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.19 (+1.40%)

USD 640.06B
0R1I:LSE NVIDIA Corp.

+4.41 (+4.43%)

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B
PRJU:LSE Amundi Index Solutions - Amund..

+0.17 (+0.54%)

USD 259.48B
0QZO:LSE 0QZO

N/A

USD 258.54B
0QZ3:LSE Qualcomm Inc.

+6.50 (+4.74%)

USD 202.26B
0R24:LSE Intel Corp.

N/A

USD 196.14B

ETFs Containing XESX:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.06% 88% B+ 82% B
Dividend Return 0.00% 6% D- 4% F
Total Return 8.06% 88% B+ 82% B
Trailing 12 Months  
Capital Gain 1.64% 46% F 53% F
Dividend Return 0.03% 22% F 18% F
Total Return 1.67% 42% F 51% F
Trailing 5 Years  
Capital Gain 78.73% 73% C 77% C+
Dividend Return 0.20% 33% F 40% F
Total Return 78.93% 71% C- 75% C
Average Annual (5 Year Horizon)  
Capital Gain 9.07% 61% D- 65% D
Dividend Return 9.08% 60% D- 65% D
Total Return 0.02% 28% F 20% F
Risk Return Profile  
Volatility (Standard Deviation) 12.65% 53% F 72% C
Risk Adjusted Return 71.81% 71% C- 82% B
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.